Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Leukotriene B4 receptor 1 (BLT1) is a high-affinity G protein-coupled receptor (GPCR) for leukotriene B4 (LTB4), a potent lipid mediator involved in inflammation and immune responses. BLT1 is primarily expressed on leukocytes, including granulocytes, macrophages, activated T cells, and certain dendritic cell subsets. It mediates chemotaxis and activation of these immune cells in response to LTB4 signaling. The LTB4–BLT1 axis plays a critical part in both host defense mechanisms against pathogens and the pathogenesis of various inflammatory diseases. Antagonists targeting this pathway have shown efficacy in reducing disease severity in animal models with inflammatory conditions.
Antagonism of LTB4 binding to BLT1, inhibiting downstream signaling cascades.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Leukotriene B4 Receptor 1 (BLT1).